遵循 Tayebat 体系、不用药物就能治愈糖尿病；例证是一位在使用胰岛素30年后停用了胰岛素的患者。
原始表述
جالي عيان راجل من تونس والراجل ده من بقىه 30 سنه بياخد انسولين بطل الانسولين من اربع شهور مشي على النظام شهرين بقى كويس
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
遵循 Tayebat 体系、不用药物就能治愈糖尿病；例证是一位在使用胰岛素30年后停用了胰岛素的患者。
出处
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! السيليوليت (打开来源)
- 发布日期
- 2025年10月11日
- 时间戳
- 0:53:37 (在原视频 YouTube 自动字幕轨中的位置；可确认该内容出现的位置，但不能确认说话人是谁)
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
- 所声称的机制
Removing harmful foods resolves the stress that raises glucose.
- 所声称的健康影响
Diabetes cure
- 涉及人群
People with diabetes
- Elawady 设定的地域限制
none found
来源版本存在差异
- 来源状态
- 视频转录文本（本人原话）
- 归属
- Elawady (machine transcript)
- 视频
- Dr Diaa Al Awady د ضياء العوضي is live! مفيش حاجه سعرات مفيش حاجه اسمها نشويات (打开来源)
- 发布日期
- 2025年8月7日
- 时间戳
- 无（转录文本不含时间信息）
- 归属的不确定性
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
科学评估
基本错误 – 该说法的主要部分没有证据支持，或被严重夸大。
证据确定性: 中 – 进一步研究仍可能影响该评估。
1. 说法是什么？
Diet cures diabetes, as shown by patients who stopped insulin on the system.
2. 哪些内容可证实是正确的？
DiRECT: remission (HbA1c <6.5% off all drugs) in 46% vs 4% at 12 months; 86% of those losing >=15 kg (I-FAST-12); 36% vs 3% at 24 months (I-FAST-13). DIADEM-I (Qatar, people from the Middle East and North Africa, diabetes <=3 years): remission 61% vs 12% after an intensive diet programme (I-DIAB-101). A meta-analysis of 18 nonsurgical RCTs found remission about six times more likely with nonpharmacological programmes (RR 5.80) (I-DIAB-103). ADA 2026 states that sustained loss of >10% body weight may lead to remission (I-DIAB-113). The archive itself recommends diet and weight loss before insulin escalation (C-INS-11).
3. 哪些内容是错误或夸大的？
Remission trials used structured low-energy programmes with medical supervision and enrolled mainly people with recent, non-insulin-treated type 2 diabetes; remission depended on weight loss, not on avoiding particular 'forbidden' foods (I-FAST-12, I-DIAB-101, I-DIAB-103). Remission mostly waned: at 5 years 10% vs 5% of the original DiRECT groups were in remission (I-FAST-14); in Look AHEAD only 3.5% stayed in remission for 4 years (I-DIAB-102). The accepted term is remission, not cure, and it requires continued follow-up (I-DIAB-104). Before insulin existed, diet and fasting could not keep insulin-deficient diabetes alive: most children died of diabetic coma within months to years and Allen wrote that 'the diabetes is not cured' (I-INS-101). Type 1 diabetes cannot be cured by diet (C-INS-07). The Tayebat system has not been tested; the cases cited are not verifiable.
4. 哪些内容仍不明确？
Whether the Tayebat dietary rules produce sufficient weight loss in practice.
5. 哪些研究支持该说法？
I-FAST-12, I-FAST-13, I-DIAB-101, I-DIAB-103, I-DIAB-113 (remission of early type 2 diabetes with major weight loss); partly I-FAST-14, I-DIAB-102, I-DIAB-104 (some long-term remission; definition).
6. 哪些研究与该说法相矛盾？
I-INS-101 (pre-insulin natural history), I-INS-03, I-ODD-16; I-FAST-14 and I-DIAB-102 (remission mostly not durable; people on insulin largely not studied).
7. 对德国和欧洲而言情况如何？
German guidance accepts remission through weight reduction as a goal in early type 2 diabetes.
8. 关于埃及的已知情况是什么？
Lifestyle-based remission programs are less established; supervision is needed when reducing drugs.
9. 合理的实际结论是什么？
早期2型糖尿病可以在医疗监督下通过大幅减重而获得缓解；药物要在监测下逐步减少。这不适用于1型糖尿病。
评估详情
- 证据确定性的依据
Split: (a) remission of early type 2 diabetes through substantial weight loss is shown in RCTs (DiRECT 46% vs 4%; DIADEM-I in a Middle Eastern population 61% vs 12%) and a 2025 meta-analysis of 18 RCTs (I-DIAB-103), but mostly in people with short diabetes duration, without insulin, under strict supervised protocols, and remission often fades (I-FAST-14, I-DIAB-102). (b) Cure of type 1 diabetes or long-standing insulin-deficient diabetes by diet is contradicted by natural-history data from the pre-insulin era (I-INS-101) and by all guidelines. (c) The Tayebat system has not been tested. Certainty is moderate (raised from low): the boundaries of diet-induced remission are now well defined by randomised evidence; the only indirectness is that the specific system is untested.
- 来源质量
Own words; anecdotal cases.
- 地区可推广性
DiRECT conducted in UK primary care; transferability to Egypt plausible if weight loss is achieved.
- 个体例外情况
Remission is most likely with short diabetes duration (<6 years), no insulin, and large sustained weight loss (>10-15 kg).
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
过度解读 – 确有真实的发现，但该说法从中引申出的结论超出了数据所能支持的范围（例如把关联当作因果、把动物数据套用到人身上、把小效应说成大效应）。
研究问题: Can diabetes, including long-standing insulin-treated diabetes, be cured by a diet without medication?
研究问题详解 (PICO)
- 人群
- People with type 1 diabetes, long-standing insulin-treated diabetes and early type 2 diabetes
- 干预或暴露
- Dietary/lifestyle programmes (including the Tayebat system)
- 对照
- Usual care with medication
- 地域范围
- universal biology; Middle East data available (DIADEM-I)
- 结局指标
- Remission (HbA1c <6.5% off drugs >=3 months)
- Durability
- DKA and harm when insulin is stopped
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
Weight-loss programme puts early type 2 diabetes into remission in Qatar
Taheri S et al.. Lancet Diabetes Endocrinol 2020 · PMID 32445735 · DOI 10.1016/S2213-8587(20)30117-0 随机对照试验已核查摘要新增DIADEM-I (Qatar): intensive diet-based weight loss in early T2D.
- 实际结果
- Remission 61% vs 12% at 12 months (OR 12.03).
- 方法学质量
- high (RCT, MENA population)
- 相关性
- direct for early T2D; indirect for the claim (no insulin users, not the Tayebat diet)
- 局限
- 12 months; open label.
Can type 2 diabetes go into remission without surgery? A review of trials
Meta-analysis of 18 nonsurgical RCTs.
- 实际结果
- Nonpharmacological remission RR 5.80 (4.28-7.87).
- 方法学质量
- high (recent SR/MA)
- 相关性
- direct for early T2D
- 局限
- Heterogeneity; overlaps with DiRECT/DIADEM-I.
DiRECT: weight loss to put type 2 diabetes into remission
DiRECT: total diet replacement in early T2D.
- 实际结果
- Remission 46% vs 4% at 12 months.
- 方法学质量
- high (cluster RCT)
- 相关性
- direct for early T2D; excluded insulin users and duration >6 years
- 局限
- Remission waned by 5 years (I-FAST-14).
哪些证据不支持该说法？
What happened to people with diabetes before insulin existed
Pre-insulin era: diet and fasting alone in insulin-deficient diabetes.
- 实际结果
- 43% of Allen's 76 patients dead within a few years; most children died from coma within months to years; 'the diabetes is not cured'.
- 方法学质量
- low (historical) but very large effect
- 相关性
- direct for type 1/insulin-deficient diabetes
- 局限
- Historical, uncontrolled.
DiRECT after five years
Lean ME et al.. Lancet Diabetes Endocrinol 2024 · PMID 38423026 · DOI 10.1016/S2213-8587(23)00385-6 随机对照试验全文，含结构化偏倚风险评估DiRECT 5-year follow-up.
- 实际结果
- Remission 10% vs 5% at 5 years in original groups.
- 方法学质量
- high (RCT follow-up)
- 相关性
- direct on durability
- 局限
- Attrition.
How often lifestyle change puts type 2 diabetes into remission (Look AHEAD)
Look AHEAD: conventional intensive lifestyle.
- 实际结果
- Remission 11.5% year 1; sustained 4 years 3.5%.
- 方法学质量
- high (large RCT, secondary analysis)
- 相关性
- direct
- 局限
- Exploratory.
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
Early type 2 diabetes can go into remission (not cure) with substantial supervised weight loss; type 1 diabetes and long-standing insulin-deficient diabetes cannot be cured by diet; the Tayebat system has not been tested.
为什么有些研究权重更大
RCTs define the boundaries of remission (early T2D, weight loss, supervision); historical and guideline evidence define the impossibility for insulin-deficient diabetes; anecdotes carry no weight.
因果关系是否已确立？ 是，已确立 Weight loss causes remission in early T2D (RCTs with dose-response); absence of insulin causes death in insulin-deficient diabetes (historical natural history).
仍存在的不确定性
Long-term durability; effect of the specific Tayebat rules (untested); the illustrative patient's diabetes type is unknown.
合理的结论
Mostly false; true only for remission of early type 2 diabetes via weight loss.
为什么研究结果看起来互相矛盾？
Remission trials (supporting) and historical/guideline evidence (contradicting) concern different populations: early T2D with preserved beta-cell function versus insulin-deficient diabetes. Ketosis-prone T2D (I-INS-128) shows that some people who present with DKA can stop insulin, but only under supervision and based on phenotype.
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- DIADEM-I shows remission is achievable in people from the Middle East and North Africa with structured weight loss.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- Absolute remission difference and NNT – 49 percentage points (35.5-62.5); NNT about 2; OR 12.03 overstates the relative effect (RR about 5.1) 已重新计算
- Absolute remission difference – Year 1: 9.5 points (NNT about 10.5); year 4: 5.3 points (NNT about 19) 已重新计算
- Absolute remission difference – 42 points (33.4-50.6); NNT about 2.4 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Remission of diabetes off medication with dietary intervention (claim as stated, incl. insulin-treated/type 1)
- 起始等级
- 高（随机试验）
- 降级理由
- indirectness (Tayebat system untested; trials in early T2D only)
- 结果
- 中
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA: 8. Obesity and Weight Management: Standards of Care in Diabetes-2026 (2026) · 原始文献
Sustained loss of >10% body weight may lead to remission of type 2 diabetes (A); weight loss reduces the need for glucose-lowering drugs, particularly insulin. - ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16). - NICE: NG28 Type 2 diabetes in adults: management (last updated 18 February 2026) (2026) · 原始文献
Low-energy and very-low-energy diets via the NHS Type 2 Diabetes Path to Remission Programme (1.3.4); evidence on stopping/switching medicines is limited (research recommendation). - ADA/EASD/Endocrine Society/Diabetes UK: Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes (PMID 34462270) (2021) · 原始文献
Remission = HbA1c <6.5% at least 3 months after stopping glucose-lowering drugs; continued observation recommended (abstract). - ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · 原始文献
'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant.
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | Taheri S[au] AND DIADEM-I | 支持性证据 | 4 | |
| Europe PMC | 2026年10月26日 | (TITLE:"remission") AND "type 2 diabetes" AND (TITLE:"meta-analysis" OR TITLE:"systematic review") AND PUB_YEAR:[2021 TO 2026] | 支持性证据 | 40 | |
| Europe PMC | 2026年10月26日 | "type 2 diabetes" AND remission AND (Egypt OR Egyptian OR Saudi OR Arab OR "Middle East") AND (diet OR lifestyle) AND (randomized OR randomised) | 支持性证据 | 1131 | |
| PubMed | 2026年10月26日 | ("type 1 diabetes") AND (diet OR "low-carbohydrate" OR "ketogenic") AND ("insulin independence" OR "stop insulin" OR "discontinue insulin" OR cure) | 支持性证据 | 23 | |
| Europe PMC | 2026年10月26日 | ("diabetes" AND ("cured" OR "cure") AND (diet OR "dietary") AND (TITLE:"insulin")) AND PUB_YEAR:[2015 TO 2026] | 支持性证据 | 289 | |
| PubMed | 2026年10月26日 | ("type 2 diabetes" AND remission) AND (insulin-treated OR "insulin therapy" OR "on insulin") AND (diet OR "low-calorie" OR "low-carbohydrate" OR "weight loss") AND (trial OR cohort) | 双向 | 20 | |
| PubMed | 2026年10月26日 | Gregg EW[au] AND remission AND "Look AHEAD" AND JAMA[ta] | 反对性证据 | 1 | |
| Europe PMC | 2026年10月26日 | (TITLE:"starvation" OR TITLE:"Allen") AND (TITLE:"diabetes") AND (TITLE:"insulin" OR TITLE:"pre-insulin") | 反对性证据 | 24 | |
| PubMed | 2026年10月26日 | "ketosis-prone" AND (insulin discontinuation OR "insulin independence" OR remission) | 双向 | 56 | |
| PubMed | 2026年10月26日 | Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes | 指南 | 8 | |
| PMC (publisher full text) | 2026年10月26日 | Fetched ADA Standards of Care 2026 sections 2, 6, 8, 10, 14, 16 at pmc.ncbi.nlm.nih.gov/articles/PMC12690183, PMC12690178, PMC12690172, PMC12690187, PMC12690182, PMC12690180 | 指南 | 6 | |
| Guideline websites (NICE) | 2026年10月26日 | Fetched https://www.nice.org.uk/guidance/ng28/chapter/Dietary-advice-and-interventions (+ Insulin-based-treatments, Individualised-care) | 指南 | 3 |
核查深度如何？
12 项相关研究：5 项核查了全文（其中 1 项进行了结构化偏倚风险评估），7 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本错误 (低)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 评定结论已更改: 基本错误 (低) → 基本错误 (中)
Verdict unchanged. Certainty raised from low to moderate: a 2025 meta-analysis of 18 RCTs and the Middle Eastern DIADEM-I trial define clearly that remission is limited to early type 2 diabetes with major weight loss, while historical natural-history data show that diet cannot replace insulin in insulin-deficient diabetes. The only remaining indirectness is that the Tayebat system itself is untested.
新来源: I-DIAB-101 I-DIAB-102 I-DIAB-103 I-DIAB-104 I-DIAB-113 I-INS-101 I-INS-128
通俗解释
在英国和卡塔尔开展的试验表明，新近确诊的2型糖尿病患者在参加结构化项目并大幅减重后，约一半或更多人可以停用所有糖尿病药物至少一年。许多人在之后的几年中复发。这一效果是通过减重并在医疗监督下实现的。在胰岛素被发现之前，单靠饮食无法让1型糖尿病患儿存活下来。具体的 Tayebat 饮食从未经过检验。
与该说法相关的研究
支持该说法的研究 (5)
-
DiRECT: weight loss to put type 2 diabetes into remission
Lean ME et al.. Lancet 2018 · PMID 29221645 · DOI 10.1016/S0140-6736(17)33102-1随机对照试验独立交叉核查已核查摘要★ 关键研究46% of people in the programme were free of diabetes and medication after one year.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Can intensive weight management in primary care achieve T2D remission?
- 研究是如何开展的？
Open-label cluster-randomised trial (DiRECT)
- 研究了多少人、动物或样本？
306 (149 per group ITT); 49 practices; Age 20-65, T2D <6 years, BMI 27-45, not on insulin
- 实际发现了什么？
Remission 46% vs 4%.
- 观察到的效应有多大？
OR 19.7
- 研究结果对日常生活意味着什么？
Losing 10-15 kg can reverse early type 2 diabetes.
- 该研究有哪些局限？
Open-label; Selected population; Formula diet
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK; directly relevant.
- 从该研究中明确不能得出什么结论？
Effect of the Tayebat diet; effect in type 1 or insulin-treated diabetes.
-
DiRECT after two years
Lean MEJ et al.. Lancet Diabetes Endocrinol 2019 · PMID 30852132 · DOI 10.1016/S2213-8587(19)30068-3随机对照试验独立交叉核查已核查摘要36% were still in remission after two years.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Durability of remission at 24 months
- 研究是如何开展的？
Cluster-randomised trial, 2-year results (DiRECT)
- 研究了多少人、动物或样本？
298 ITT; As DiRECT
- 实际发现了什么？
Remission 36% vs 3%.
- 观察到的效应有多大？
aOR 25.82
- 研究结果对日常生活意味着什么？
Sustained weight loss keeps diabetes away.
- 该研究有哪些局限？
Open-label
- 它对 Elawady 的具体说法说明了什么？
Supports C-DIAB-03.
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Long-term outcomes.
-
Weight-loss programme puts early type 2 diabetes into remission in Qatar
Taheri S et al.. Lancet Diabetes Endocrinol 2020 · PMID 32445735 · DOI 10.1016/S2213-8587(20)30117-0随机对照试验独立交叉核查已核查摘要★ 关键研究61% of young adults with recent type 2 diabetes reached remission after an intensive diet programme, versus 12% with usual care.
Remission 61% vs 12% in early T2D (MENA population) with structured weight loss.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Test intensive lifestyle therapy for early T2D in the MENA region.
- 研究是如何开展的？
Randomised trial.
- 研究了多少人、动物或样本？
158 adults, diabetes <=3 years.
- 实际发现了什么？
Weight -12 kg; remission 61% vs 12%.
- 观察到的效应有多大？
Difference 49 points; NNT about 2.
- 研究结果对日常生活意味着什么？
Early type 2 diabetes can go into remission with major weight loss under supervision.
- 该研究有哪些局限？
12 months; open label; no insulin users.
- 它对 Elawady 的具体说法说明了什么？
Supports the kernel for early T2D only.
- 研究结果是否适用于德国和欧洲？
Matches UK DiRECT.
- 从该研究中明确不能得出什么结论？
Cannot support stopping insulin or curing T1D.
-
Can type 2 diabetes go into remission without surgery? A review of trials
Sherifali DT et al.. Diabetes Care 2025 · PMID 40982327 · DOI 10.2337/dc25-0562Meta分析独立交叉核查已核查全文★ 关键研究Structured diet and lifestyle programmes made remission about six times more likely, mainly in people with recently diagnosed type 2 diabetes.
Remission RR 5.80 for nonpharmacological interventions, mainly early, insulin-naive T2D.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pool RCTs of nonsurgical remission.
- 研究是如何开展的？
Meta-analysis of 18 RCTs.
- 研究了多少人、动物或样本？
11 countries.
- 实际发现了什么？
RR 5.80 (nonpharmacological).
- 观察到的效应有多大？
RR 1.75-5.80.
- 研究结果对日常生活意味着什么？
Early type 2 diabetes can go into remission with strict programmes.
- 该研究有哪些局限？
Heterogeneity; short follow-up.
- 它对 Elawady 的具体说法说明了什么？
Supports the T2D kernel, not cure of T1D or long-standing insulin-treated diabetes.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot show permanent cure.
-
US diabetes standards 2026: weight loss and type 2 diabetes
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008指南 / 立场声明独立交叉核查已核查全文★ 关键研究Losing more than 10% of body weight can lead to remission of type 2 diabetes and reduce the need for insulin.
>10% weight loss may lead to T2D remission (grade A).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide weight management.
- 研究是如何开展的？
Guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Weight loss >10% may induce remission.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Weight loss is a powerful treatment for type 2 diabetes.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Supports the T2D kernel of C-DIAB-03.
- 研究结果是否适用于德国和欧洲？
European guidance agrees.
- 从该研究中明确不能得出什么结论？
Not applicable to T1D.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (3)
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401随机对照试验独立交叉核查已核查摘要★ 关键研究Intensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- 研究是如何开展的？
Multicentre RCT (DCCT)
- 研究了多少人、动物或样本？
1,441; Insulin-dependent (type 1) diabetes
- 实际发现了什么？
Large reductions in all microvascular complications.
- 观察到的效应有多大？
Retinopathy -76%
- 研究结果对日常生活意味着什么？
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- 该研究有哪些局限？
Open-label; Selected young population
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
North American; universally accepted.
- 从该研究中明确不能得出什么结论？
Effects in type 2 diabetes directly.
-
ADA guideline 2026: diabetes medicines
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pharmacologic glycaemic treatment
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- 研究了多少人、动物或样本？
not applicable; People with type 1 and type 2 diabetes
- 实际发现了什么？
See results.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Medicines chosen by benefit-risk.
- 该研究有哪些局限？
Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with ADA/EASD consensus.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
What happened to people with diabetes before insulin existed
Mazur A. Nutr J 2011 · PMID 21396115 · DOI 10.1186/1475-2891-10-23叙述性综述独立交叉核查已核查全文★ 关键研究Before 1922, children with diabetes usually died of diabetic coma within months to a few years, even on strict fasting diets; some starved to death.
'The diabetes is not cured' (Allen); diet could not substitute for insulin.
该研究是否支持这一具体说法？ 否 · 方法学质量: 低 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
To explain why fasting diets were used for diabetes before insulin and how patients fared.
- 研究是如何开展的？
Historical analysis of published case series and textbooks.
- 研究了多少人、动物或样本？
Patients of Allen (76 published cases) and Joslin, 1914-1922.
- 实际发现了什么？
Most children died of coma within months to years; 43% of Allen's cases were dead by 1917; four died of starvation; diabetes was not cured.
- 观察到的效应有多大？
43% mortality within a few years (Allen's series).
- 研究结果对日常生活意味着什么？
Diet and fasting alone cannot keep insulin-deficient diabetes alive; insulin changed this.
- 该研究有哪些局限？
Historical, uncontrolled data; diabetes types not distinguished.
- 它对 Elawady 的具体说法说明了什么？
Contradicts claims that diet can replace insulin or that ketoacidosis does not kill.
- 研究结果是否适用于德国和欧洲？
Universal biology.
- 从该研究中明确不能得出什么结论？
Cannot give exact survival curves or separate type 1 from type 2 cases.
该组中没有被标记为关键研究的研究。
结果不一或不明确的研究 (4)
-
DiRECT after five years
Lean ME et al.. Lancet Diabetes Endocrinol 2024 · PMID 38423026 · DOI 10.1016/S2213-8587(23)00385-6随机对照试验独立交叉核查全文，含结构化偏倚风险评估Only 13% of those continuing support were still in remission at 5 years; people with long diabetes or on insulin were not studied.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Outcomes at 5 years with continued low-intensity support
- 研究是如何开展的？
5-year extension study of a cluster-randomised trial (DiRECT)
- 研究了多少人、动物或样本？
85 extension; 149 controls; DiRECT participants
- 实际发现了什么？
Remission declines over time.
- 观察到的效应有多大？
13% remission at 5 years
- 研究结果对日常生活意味着什么？
Remission needs ongoing weight maintenance.
- 该研究有哪些局限？
Extension group self-selected; many missing data (especially controls); open-label; only people with diabetes under 6 years and not on insulin.
- 它对 Elawady 的具体说法说明了什么？
Supports and limits C-DIAB-03 (durability).
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Cure; remission in long-standing insulin-treated diabetes; effect of any diet other than this low-calorie programme.
-
How often lifestyle change puts type 2 diabetes into remission (Look AHEAD)
Gregg EW et al.. JAMA 2012 · PMID 23288372 · DOI 10.1001/jama.2012.67929随机对照试验独立交叉核查已核查摘要★ 关键研究About 1 in 9 people reached remission in the first year with an intensive lifestyle programme, but only 3.5% stayed in remission for 4 years.
Remission possible (11.5% year 1) but rarely sustained (3.5% for 4 years).
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Measure remission in a lifestyle trial.
- 研究是如何开展的？
Analysis of a large RCT.
- 研究了多少人、动物或样本？
4,503 adults.
- 实际发现了什么？
11.5% vs 2.0% (year 1); 3.5% sustained 4 years.
- 观察到的效应有多大？
NNT about 10 (year 1).
- 研究结果对日常生活意味着什么？
Lifestyle helps, but lasting remission is uncommon.
- 该研究有哪些局限？
Exploratory analysis.
- 它对 Elawady 的具体说法说明了什么？
Contradicts 'cure' as a typical outcome.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot apply to T1D.
-
What 'remission' of type 2 diabetes means
Riddle MC et al.. Diabetes Care 2021 · PMID 34462270 · DOI 10.2337/dci21-0034指南 / 立场声明独立交叉核查已核查摘要★ 关键研究Remission means HbA1c below 6.5% at least 3 months after stopping diabetes drugs; it is not called a cure and needs ongoing checks.
Remission (not cure) of T2D is recognised; requires follow-up.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Define T2D remission.
- 研究是如何开展的？
Expert consensus.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
HbA1c <6.5% >=3 months off drugs.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Remission is possible but needs follow-up.
- 该研究有哪些局限？
Consensus.
- 它对 Elawady 的具体说法说明了什么？
Qualifies 'cure'.
- 研究结果是否适用于德国和欧洲？
Co-published in Europe.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Who can stop insulin after a first episode of ketoacidosis?
Raubenheimer PJ et al.. Diabetologia 2024 · PMID 38240751 · DOI 10.1007/s00125-023-06067-3队列研究独立交叉核查已核查摘要★ 关键研究In Cape Town, about a quarter of adults could stay off insulin for 5 years, mostly those with a type 2-like profile; people with type 1 antibodies rarely could.
Insulin independence depends on diabetes type and beta-cell reserve, not on a diet.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Find predictors of insulin independence after DKA.
- 研究是如何开展的？
Prospective cohort with supervised weaning.
- 研究了多少人、动物或样本？
88 adults.
- 实际发现了什么？
46% at 1 year, 26% at 5 years off insulin; antibodies predict dependence.
- 观察到的效应有多大？
OR 11.5 (acanthosis); 0.10 (antibodies).
- 研究结果对日常生活意味着什么？
Stopping insulin is possible for some people with a specific type 2 profile, under medical supervision only.
- 该研究有哪些局限？
Small study.
- 它对 Elawady 的具体说法说明了什么？
Partly qualifies 'nobody can stop insulin'; contradicts stopping it in type 1.
- 研究结果是否适用于德国和欧洲？
Phenotype rarer in Europe.
- 从该研究中明确不能得出什么结论？
Cannot support stopping insulin without testing and supervision.
该组中没有被标记为关键研究的研究。
地区背景
德国 / 欧盟
German guidance accepts remission through weight reduction as a goal in early type 2 diabetes.
埃及
Lifestyle-based remission programs are less established; supervision is needed when reducing drugs.
在我的国家适用什么？
一般科学评估
基本错误 早期2型糖尿病可以通过在医疗监督下大幅减重而获得缓解，但这不是治愈，也不适用于1型糖尿病或大多数长期使用胰岛素治疗的糖尿病；“Tayebat 体系能治愈糖尿病”的说法缺乏依据。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial.. Lean ME et al.. Lancet 2018 · PMID 29221645 · DOI 10.1016/S0140-6736(17)33102-1
- Durability of a primary care-led weight-management intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial.. Lean MEJ et al.. Lancet Diabetes Endocrinol 2019 · PMID 30852132 · DOI 10.1016/S2213-8587(19)30068-3
- Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial.. Taheri S et al.. Lancet Diabetes Endocrinol 2020 · PMID 32445735 · DOI 10.1016/S2213-8587(20)30117-0
- Type 2 Diabetes Remission: A Systematic Review and Meta-analysis of Nonsurgical Randomized Controlled Trials.. Sherifali DT et al.. Diabetes Care 2025 · PMID 40982327 · DOI 10.2337/dc25-0562
- 8. Obesity and Weight Management for the Prevention and Treatment of Diabetes: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358882 · DOI 10.2337/dc26-S008
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
- Why were "starvation diets" promoted for diabetes in the pre-insulin period?. Mazur A. Nutr J 2011 · PMID 21396115 · DOI 10.1186/1475-2891-10-23
- 5-year follow-up of the randomised Diabetes Remission Clinical Trial (DiRECT) of continued support for weight loss maintenance in the UK: an extension study.. Lean ME et al.. Lancet Diabetes Endocrinol 2024 · PMID 38423026 · DOI 10.1016/S2213-8587(23)00385-6
- Association of an intensive lifestyle intervention with remission of type 2 diabetes.. Gregg EW et al.. JAMA 2012 · PMID 23288372 · DOI 10.1001/jama.2012.67929
- Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes.. Riddle MC et al.. Diabetes Care 2021 · PMID 34462270 · DOI 10.2337/dci21-0034
- Phenotype and predictors of insulin independence in adults presenting with diabetic ketoacidosis: a prospective cohort study.. Raubenheimer PJ et al.. Diabetologia 2024 · PMID 38240751 · DOI 10.1007/s00125-023-06067-3